• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

PKC412

Product ID P4008
Cas No. 120685-11-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $240.10 In stock
5 mg $960.30 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

PKC412 is an anti-metastatic and anticancer chemotherapeutic staurosporine derivative that inhibits FMS-like tyrosine kinase 3 (FLT3) and is currently in clinical trials as a potential treatment for acute myelogenous leukemia (AML). PKC412 also inhibits PKC. In keloid-derived fibroblasts, PKC412 increases activity of caspase 3, inducing apoptosis. In animal models of melanoma, PKC412 inhibits metastasis and platelet-aggregating activity. This compound also alters differentiation patterns of dendritic cells ex vivo.

Product Info

Cas No.

120685-11-2

Purity

≥98%

Formula

C35H30N4O4

Formula Wt.

570.64

Synonym

Midostaurin, 4'-N-Benzoyl staurosporine

Melting Point

235-260°C

Solubility

DMSO, Dichloromethanol

Appearance

Off white powder

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

P4008 MSDS PDF

Info Sheet

P4008 Info Sheet PDF

References

Fischer T, Stone RM, Deangelo DJ, et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol. 2010 Oct 1;28(28):4339-45. PMID: 20733134.

Huang YC, Shieh HR, Chen YJ. Midostaurin (PKC412) modulates differentiation and maturation of human myeloid dendritic cells. Toxicol In Vitro. 2010 Sep;24(6):1705-10. PMID: 20685248.

Stölzel F, Steudel C, Oelschlägel U, et al. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells. Ann Hematol. 2010 Jul;89(7):653-62. PMID: 20119833.

Nakazono-Kusaba A, Takahashi-Yanaga F, Miwa Y, et al. PKC412 induces apoptosis through a caspase-dependent mechanism in human keloid-derived fibroblasts. Eur J Pharmacol. 2004 Aug 23;497(2):155-60. PMID: 15306200.

Yoshikawa N, Nakamura K, Yamaguchi Y, et al. Effect of PKC412, a selective inhibitor of protein kinase C, on lung metastasis in mice injected with B16 melanoma cells. Life Sci. 2003 Feb 7;72(12):1377-87. PMID: 12527035.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only